

Corporate Update

October 2022



NYSE American: NBY





Forward-Looking Statements

This presentation contains forward-looking statements, within the meaning of applicable U.S. securities laws, which statements can, in some cases, be identified with terms such as "project," "believe," "may," "plan," "will," "estimate," "continue," "anticipate," "intend," "expect," "target," "potential" and other similar expressions. These forward-looking statements reflect NovaBay's current expectation and assumptions, such as expected market potential and market acceptance of our products and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed in the Company's filings with the SEC, which filings can be found at www.sec.gov. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable U.S. securities laws.



Corporate Overview

Established, High-Margin Brands

- Avenova is the #1 antimicrobial lid & lash spray in the US dry eye market
- DERMAdoctor acquisition (Nov'21) expanded portfolio into skincare market
- PhaseOne and NeutroPhase cutting-edge wound care technology

Complementary Product Lines

- · Innovative, proprietary OTC products address underserved customer needs
- Similar customer demographic across all brands
- Scientifically developed and clinically proven *-not cosmetic*

Clear Path to Profitability

- Complementary sales & marketing skillsets create a strong, fast-growing company
- · Expanding distribution and international reach
- · Creating science-based, problem-solving, accessible solutions for improved well-being



Avenova for Eye Care



DERMAdoctor for Skin Care



PhaseOne & NeutroPhase for Wound Care



Investment Highlights

Predictable, Recurring Revenue

Drive future success from current
Avenova and DERMAdoctor
customers and brands. \$10.1 million
net sales in trailing twelve months

Multipronged Product Strategy

Accelerate topline growth from
existing products with expanded DTC
digital marketing and pursue new
OTC product launches in eyecare and
skincare markets

Improving Operating Margin

Leveraging DERMAdoctor's warehouse facility and NovaBay's corporate functions. 2 locations (HQ: San Francisco, CA, DD: Kansas City, MO) and 32 employees.

Well Capitalized

Current financing expected to be sufficient to fund 2023 operations including new product creation and international expansion



Execution on Growth

01

New Products Launches





DERMAdoctor Distribution Expansion

Domestic distribution expansion with Costco and QVC

International distribution expansion in China (Tmall + UNQ) and European union



Avenova Demographic Expansion

Avenova expanding into the eyelash extension market





Introducing Our Executive Team



Justin M. Hall, Esq.
Chief Executive Officer

Justin Hall joined NovaBay in February 2013 and currently serves as Company's Chief Executive Officer & General Counsel responsible for overseeing all company operations, including sales, manufacturing, and business development. Mr. Hall previously served as the Corporate Counsel of Accuray Incorporated, a radiation oncology company, where provided substantive legal advice on a broad range of complex legal matters. Mr. Hall received a B.A. in Business Administration and Management from the University of California, San Diego, and a J.D. from the University of San Diego School of Law.



Andrew Jones
Chief Financial Officer

Andrew Jones joined NovaBay in May 2020 as Chief Financial Officer. He previously served as Vice President, Finance of MyoScience, Inc., a commercial stage medical device company, through its acquisition by Pacira BioSciences. In this position, he was responsible for overseeing all accounting and finance functions as well as executive management and board-level reporting, including strategic planning decisions that resulted in significant revenue growth and gross margin improvements. Prior to MyoScience, Mr. Jones was at Armetheon, Inc., Asante Solutions, Inc., and PricewaterhouseCoopers. Mr. Jones holds a BA in business administration from the University of Washington.



Audrey Kunin, M.D.
Chief Product Officer

Audrey Kunin, M.D. joined NovaBay in November 2021 as Chief Product Officer. Dr. Kunin is a board-certified dermatologist, author, clinician, educator and the Founder of DERMAdoctor. Establishing herself as a trailblazer in the industry, Dr. Kunin created DERMAdoctor to address the all-too common skincare concerns that were overlooked in the beauty industry, providing a hassle-free, highly effective, prestige treatment for these conditions, problem-solving without irritation and with no prescription necessary. Dr. Kunin is also an accomplished radio and television talk show guest and has graced the pages of top consumer magazines.



Executing on Business Strategy

NovaBay Pharmaceuticals
Announces Significant Orders for
DERMAdoctor's Top-Selling
Kakadu C Anti-Aging Serum
ahead of the Holiday Season

Oct. 18, 2022

NovaBay Pharmaceuticals'
DERMAdoctor Products Now
Available at Target.com and
Urbanoutfitters.com

July 21, 2022

NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Showcase DERMAdoctor's Eczema Balm on Return QVC® Appearance

Sept. 12, 2022

NovaBay Pharmaceuticals
Reports Record Avenova Sales
During Amazon's Prime Day
Event

July 15, 2022

NovaBay Pharmaceuticals
Targets New Market with
Antimicrobial Avenova Lid and
Lash Spray for Lash Extensions

July 28. 2022

NovaBay Pharmaceuticals
Introduces Hydrating Cleansing
Oil to its DERMAdoctor Calm
Cool + Corrected Product Line

April 1, 2022



AVENOVA®



purely yov™



AVENOVA® purely you


Science for sore eyes.

- No. 1 Doctor-Recommended Antimicrobial Lid & Lash Spray
- Pioneering use of hypochlorous acid (HOCI) a substance naturally produced by the body — for antimicrobial lid & lash spray
- Kills a broad spectrum of bacteria and helps relieve chronic eye conditions like dry eye, blepharitis, styes, contact lens discomfort and inflammation
- 510(k) FDA-cleared formulation is the only known stable, truly pure HOCI commercial solution
- Manufactured and lab tested in the U.S. and clinically proven to be the most effective lid & lash solution available without a prescription
- 80-100 times more potent than Clorox bleach yet completely nontoxic



Avenova Efficacy Advantages

Inferior formulation and packaging by competitors can result in an ineffective solution and may contain harmful impurities such as bleach, plastic leachables and detergents





















The Avenova Difference.



Purest, longest-lasting formulation of HOCl
No stinging or irritation
Non-toxic and non-sensitizing
Completely safe for regular, long-term use

safe for everyone!



Avenova Sales Channels



Rx - Retail Pharmacy

Physicians prescribe Avenova Rx 40mL and patients fill prescriptions at a pharmacy of their choice (CVS, Walgreens, Walmart, Rite Aid, etc.)

Rx - Partner Pharmacy

- Physicians prescribe Avenova Rx 40mL and send it to a designated Avenova partner pharmacy
- Our 10 Partner Pharmacies nationwide offer a predesignated price for both insured and uninsured patients



Physician Dispensed

- Physicians purchase Avenova Rx 20mL, at a discounted price, and dispense the product through their offices
- Offers a one-stop shop experience for patient convenience
- Helps ensure patients use Avenova correctly for best results
- Creates a revenue stream for physician practices



OTC

- Physicians refer patients to Avenova.com, Amazon, Walmart & **CVS**
- Available 24/7 for customer convenience
- Physicians can provide patients with a one-time discount code on Avenova.com



The Avenova Rx sales channel seeds and fosters growth in all sales channels which maintains Avenova's market leadership position as the #1 doctor recommended product.




Avenova Opportunities for Growth



Rx + Retail Pharmacy

- Partnership with ImprimisRx, the nations largest ophthalmic compounding pharmacy
- Rx version of Avenova available at 99% of retail pharmacies nationwide



Physician Dispensed

- Promoted through targeted email sequencing campaigns
- Using online tools for broader reach without increasing the sales organization
- · Promote physician self-serve ordering through Avenova.com




OTC

- Easy access to Rx-strength product without a prescription
- · Helps offset impact of high-deductible healthcare plans
- Provides stable gross-to-net pricing
- Benefits from "Doctor Recommended" halo effect from the Rx channel







Rapid Uptake with Avenova DTC Strategy

- Vast majority of unit sales are currently through OTC channel, less than 3 years from non-prescription product launch
- Broad product accessibility through major online retailers and in-store stocking at CVS
 - Online "Subscribe & Save" feature on Avenova.com and Amazon.com, for repeat orders and revenue stabilization, now represents 17% of monthly online sales
- Core expertise in DTC digital marketing supports expansion of customer base











Complete Dry Eye Product Portfolio

One product for each step in the standard dry eye treatment regimen





Addressing a New Demographic: Lash Extensions

Expansion into new, younger demographic for Avenova

Creates cross-selling opportunities by demographic overlap with DERMAdoctor customers

Ideal cleanser to make your long lashes last longer

Lash extensions harbor extra bacteria increasing the risk of lid infections

- Can't rub eyes, requiring extra care in face washing
- Eye makeup needs removal without pulling out or wearing down lashes
- Oil-based makeup removers, cleansers, facial hydration and oil-serum hybrids cause glue to dissolve







DERMAdoctor: Established Brand in Growing Skincare Market



Established Brand

- Founded in 1998 by Drs.

 Audrey and Jeff Kunin
- Over 30 high-quality skincare products

Scientifically Formulated Proprietary Products

- Created by board-certified dermatologist
- Focus on alleviating and healing common skin conditions: dry skin, blemishes, keratosis pilaris and aging
- Effective, hypoallergenic, and problem-solving

Significant Global Growth Opportunity

- Cosmetic skincare products estimated to reach \$185 billion by 2027
- The skincare segment is growing faster than any other part of the beauty industry

DERMAdoctor delivers on the promise that clinical skin therapy can be fun and easy, while delivering significant, measurable results



Leveraging the Brand

DERMAdoctor







Primary Product Families

Kakadu C

Vitamin C based elixirs with anti-aging properties





KP Duty

Exfoliating body treatments targeting keratosis pilaris to alleviate dry, rough, bumpy skin





AIN'T misbehavin'

Suite of solutions for acne and related conditions





Calm Cool + Corrected

Created for irritable, itchy, red, inflamed skin cause by eczema, rosacea and seborrheic dermatitis

Page



DERMAdoctor Sales Channels



















SkinStore















Current Int'l Distribution

- Middle East (Kuwait, UAE, Qatar, SA)
- · Great Britain
- Central America
- South America

Expansion Opportunities

- China
- European Union





New Partners Enhance Marketing in China

Major growth opportunity with new partners

- Tmall store (Amazon equivalent) upgraded with Duomai
- UNQ to provide additional influencer marketing

Growing market for functional skincare products

- China market expected to exceed \$100 billion by 2024
- Accounting for >22% of the total Chinese skincare market















WOUND CARE



Cutting Edge Wound Care Technology





- The safe and effective HOCI solution for managing viruses, bacteria and fungi
 - Leverages NovaBay proprietary HOCI technology
 - Rx product for routine and tough cases
- PhaseOne Health (U.S.)
 Pioneer Pharma (China)



SUMMARY



Past and Future Milestone





Financial, Operational, and Investment Highlights

Predictable, Recurring, and Growing Revenue

- \$10.1 million TTM net sales
- 18% year-over-year increase in Avenova spray OTC unit sales
- Strong seasonality in second half of the year for DERMAdoctor

Multipronged Commercial Growth Strategy

- New OTC product launches
- International expansion
- More effective digital & social marketing capabilities

Improving Profitability

- Top-line growth
- Fulfillment efficiencies
- In-house marketing capabilities
- Combined back-office functions

Well Capitalized

- Closed \$2M tranche in Sept'22
- Closing \$3M tranche in Nov'22
- Anticipated cash in excess of \$5M at year-end
- Funding is adequate for 2023 operating expenses and all growth initiatives